$4.600
+0.010 (+0.22%)Zum Schluss
EVH-News
EVH-Events
2026 Revenue Consensus at $2.5B, Adjusted EBITDA Guidance Tightened to $120M-$135M
2026 revenue consensus $2.5B. Tightens adjusted EBITDA guidance to $120M-$135M. Expects to deploy $25M-$30M in cash for capitalized software development during 2026.
Evolent Reports Q2 Revenue of $652.52M, Beating Consensus
Reports Q2 revenue $652.52M, consensus $599.79M. CEO Seth Blackley stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure." CFO Mario Ramos stated, "Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150M driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility."
Evolent Q1 Revenue at $496.25M, Below Consensus
Reports Q1 revenue $496.25M, consensus $534.04M. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna. As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opportunity we have with AI, all while fulfilling our commitments to shareholders, employees and customers."
Evolent Health Appoints Archie Mayani as Chief Product Officer
Evolent Health announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer, CPO. Before joining Evolent, she served as CPO at GHX.
Oppenheimer Lowers Evolent Health Price Target to $6
Oppenheimer lowered the firm's price target on Evolent Health to $6 from $12 and keeps an Outperform rating on the shares following the company's Q4 earnings release and newly issued guidance. The firm is lowering FY2026/2027 EPS estimates and issuing an initial FY2028 EPS estimate. Overall, Oppenheimer believes the more conservative posture toward reserves and the upside to margins from the significant new business, sets the company up for outsized growth in the coming years.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.